Ntla stock zacks
Intellia Therapeutics Inc. company facts, information and stock details by MarketWatch. View ntla business summary and other industry information. 12/30/2019 · Real time Intellia Therapeutics (NTLA) stock price quote, stock graph, news & analysis. Has Intellia Therapeutics (NTLA) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out. Intellia Therapeutics is one of 881 individual stocks in the Medical sector. Collectively, these companies sit at #2 in the Zacks Sector Rank. Intellia Therapeutics Inc fell by -1.25% in the last day ( Thursday, 26th Dec 2019 ) from $16.04 to $15.84 During the day the stock fluctuated 2.87% from a day low at $15.70 to a day high of $16.15. The price has risen in 6 of the last 10 days , but is still down by -3.94% for this period. 12/31/2019 · NTLA: Get the latest Intellia Therapeutics stock price and detailed information including NTLA news, historical charts and realtime prices. Intellia Therapeutics (NASDAQ:NTLA) was upgraded by Zacks Investment Research from a “hold” rating to a “strong-buy” rating in a research report issued to clients and investors on Wednesday, Zacks.com reports. The brokerage presently has a $15.00 price target on the stock.
The latest closing stock price for Intellia Therapeutics as of December 23, 2019 is 15.82. The all-time high Intellia Therapeutics stock closing price was 34.95 on March 09, 2018. The Intellia Therapeutics 52-week high stock price is 19.00, which is 20.1% above the current share price.
Brokerages expect that Intellia Therapeutics Inc (NASDAQ:NTLA) will report ($0.53) earnings per share for the current quarter, Zacks reports. Six analysts have provided estimates for Intellia Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.64) and the highest estimate coming in at ($0.47). Click the Predict button to answer the prediction request. Test your skills and become famous. Best predictor for any stock is listed at the stock pages. Has Intellia Therapeutics (NTLA) Outpaced Other Medical Stocks This Year? Zacks 2 days ago; Stocks With Rising Relative Strength: Intellia Therapeutics Investor's Business Daily Dec 13, 2019; Intellia Therapeutics Shows Rising Price Performance With Jump To 84 RS Rating Investor's Business Daily Dec 04, 2019 NTLA Description — Intellia Therapeutics Inc. Intellia Therapeutics is a genome editing company focused on developing therapeutics utilizing a biological tool known as Clustered, Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR associated 9 (Cas9). Zacks Investment Research upgraded shares of Intellia Therapeutics (NASDAQ:NTLA) from a hold rating to a buy rating in a research note published on Tuesday, Zacks.com reports. They currently have $20.00 price target on the stock. Van Meerten Stock Picks. Jim Van Meerten's Daily Stock Picks highlights stocks you might want to consider for your portfolio, with Jim's editorials about current events and stock market commentary. Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.
Intellia Therapeutics (NASDAQ:NTLA) was upgraded by Zacks Investment Research from a “hold” rating to a “strong-buy” rating in a research report issued to clients and investors on Wednesday, Zacks.com reports. The brokerage presently has a $15.00 price target on the stock.
6/1/2018 · Chicago, IL - June 1, 2018 - Today, Zacks Investment Ideas feature highlights Features: CRISPR Therapeutics CRSP, Intellia Therapeutics NTLA, Editas 10/14/2016 · AMARIN CORP PLC (AMRN): Free Stock Analysis Report. INTELLIA THERAP (NTLA): Free Stock Analysis Report. To read this article on Zacks.com click here. Zacks Investment Research. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Intellia Therapeutics Inc. company facts, information and stock details by MarketWatch. View ntla business summary and other industry information.
Analyzing Gilead Sciences (Nasdaq:GILD) stock? View GILD's stock price, price target, dividend, earnings, financials, forecast, insider trades, news, and SEC filings at MarketBeat.
12/30/2019 · Real time Intellia Therapeutics (NTLA) stock price quote, stock graph, news & analysis.
For stock investors, the falling rates environment is now favoring one particular sector: consumer staples.
View NTLA's most recent analyst ratings, analyst estimates and price targets at MarketBeat. MarketBeat - Stock Market News and Research Tools logo. Intellia Therapeutics (NASDAQ:NTLA) Price Target and Consensus Rating Fundamental company data provided by Morningstar and Zacks Investment Research. Get today's Intellia Therapeutics Inc stock price and latest NTLA news as well as Intellia Therapeutics Inc real-time stock quotes, Zacks Investment Research. Intellia Therapeutics, Inc. (NASDAQ:NTLA) has 149 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Intellia Therapeutics Market Cap 2015-2019 | NTLA. Prices · Financials · Revenue 2019 is $0.72B. Compare NTLA With Other Stocks Stock Name, Country, Market Cap, PE Ratio.. Fundamental data from Zacks Investment Research, Inc. ODT: Get the latest Odonate Therapeutics stock price and detailed information Zacks.com featured highlights include: Odonate Therapeutics, Novavax, Beazer NTLA for a $14.65 credit, down 57 cents, resulting in a 3.8% loss over 12 days. For my strategy portfolios, I require that stocks have a Zacks rank of 1 for entry, 10 hours ago Intellia Therapeutics (NASDAQ:NTLA) was downgraded by Zacks Investment Four equities research analysts have rated the stock with a hold
Get breaking news and analysis on Intellia Therapeutics, Inc. (NTLA) stock, price quote and chart, trading and investing tools. Stock quote for Intellia Therapeutics, Inc. Common Stock Common Stock (NTLA) with real-time last sale and extended hours stock prices, company news, charts, and Intellia Therapeutics, Inc. (NTLA) Reports Q3 Loss, Lags Revenue Estimates Zacks 07:30AM Intellia Therapeutics Announces Third Quarter 2018 Financial Results and Corporate Developments GlobeNewswire NTLA, Intellia Therapeutics - Stock quote performance, technical chart analysis, SmartSelect Ratings, Group Leaders and the latest company headlines 6/1/2018 · Chicago, IL - June 1, 2018 - Today, Zacks Investment Ideas feature highlights Features: CRISPR Therapeutics CRSP, Intellia Therapeutics NTLA, Editas